Current News

Contact | Print version | Send article | RSS feed

SR Pharma plc Announces Encouraging Results for Atu027 RNAi Showing Therapeutic Efficacy in Mouse Models of Pancreatic Cancer

15 Sep 2006 - SR Pharma plc and its operating subsidiary Atugen AG announce that studies at the Charité Hospital, Berlin have demonstrated the therapeutic efficacy of Atu027 RNAi in animal models of pancreatic cancer. The data showed both inhibition of cancer growth and prevention of metastatic spread, demonstrating potent efficacy and effective delivery, with no adverse events. These promising data support the clinical development program for Atu027 RNAi for pancreatic cancer which is scheduled to enter human clinical trials in 2007. Atu027 RNAi is an novel therapeutic drug being developed based on small interfering RNA.
 
Atugen has concentrated its efforts to meet this medical need by developing Atu027 RNAi. In these studies, mice with human pancreatic cancer were injected with Atu027 RNAi, a modified and stabilized small interfering RNA drug, formulated in a proprietary liposomal based delivery system (AtuPLEX). Atu027 RNAi works by specifically targeting PKN3, a proprietary protein kinase target.